The DF/HCC GI SPORE Career Development Program (CDP) is designed to provide the incentive and structure necessary to attract junior investigators in basic, translational and clinical research into GI cancer. The overall goal of the CDP is to nurture the success of talented new researchers in GI cancer. By providing research support and exposure to the GI SPORE investigators, we hope to promote the independent research careers of junior faculty. Moreover, the SPORE CDP strives to attract minority and female investigators to the field of GI cancer. The investigators assembled in the DF/HCC GI SPORE have a substantial record in mentorship of junior faculty working in GI cancer research. The GI SPORE CDP has established a formal process for the identification, selection, and mentoring of individuals pursuing careers in the study of basic, clinical, and population science-based aspects of GI cancer. The CDP Governance and Review Committee, led by outstanding senior mentors across BWH, MGH, DFCI, and BIDMC, direct a program that ensures optimal selection, support, and oversight of the GI SPORE CDP. Over the past funding cycle, the CDP has selected, funded, and mentored 15 talented young investigators in GI cancer who have made exceptional career development as well as substantial contributions to the field of GI cancer.
The Specific Aims of the Career Development Program are: 1. Establish a system to identify promising young investigators seeking to become independent investigators in GI cancer research. 2. Provide funding and resources and monitor awardee progress. 3. Promote a mentoring environment in the SPORE that will assist in the career development of CDP awardees as well as other junior faculty. 4. Train and develop the next generation of leaders in GI cancer translational investigation.
Career development of young faculty is vital to the continued progress in reducing the burden of GI cancer. The DF/HCC GI SPORE Career Development Program (CDP) is designed to provide the incentive and structure necessary to attract junior investigators in basic, translational and clinical research to focus on key issues in GI cancer.
|Ananthakrishnan, Ashwin N; Du, Mengmeng; Berndt, Sonja I et al. (2015) Red meat intake, NAT2, and risk of colorectal cancer: a pooled analysis of 11 studies. Cancer Epidemiol Biomarkers Prev 24:198-205|
|Song, Mingyang; Gong, Jian; Giovannucci, Edward L et al. (2015) Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer 137:154-64|
|Lochhead, Paul; Chan, Andrew T; Nishihara, Reiko et al. (2015) Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol 28:14-29|
|Inamura, Kentaro; Yamauchi, Mai; Nishihara, Reiko et al. (2015) Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol 22:1226-35|
|Serrano, César; Wang, Yuexiang; Mariño-Enríquez, Adrián et al. (2015) KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol 33:e93-6|
|Rosenthal, Michael H; Kim, Kyung Won; Fuchs, Charles S et al. (2015) CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal cancer. Abdom Imaging 40:1170-6|
|Wu, Chen; Kraft, Peter; Stolzenberg-Solomon, Rachael et al. (2014) Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut 63:152-60|
|Arteaga, Carlos L; Engelman, Jeffrey A (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25:282-303|
|Blaszkowsky, L S; Ryan, D P; Szymonifka, J et al. (2014) Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann Oncol 25:121-6|
|Ma, Tianle; Jang, Eun Jeong; Zukerberg, Lawrence R et al. (2014) Recurrences are common after endoscopic ampullectomy for adenoma in the familial adenomatous polyposis (FAP) syndrome. Surg Endosc 28:2349-56|
Showing the most recent 10 out of 259 publications